Please assess the completion status of the following clinical trial:

Trial Title: Androgen Effects in HIV-infected Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female 18 - 55~* BMI less than or equal to 26~* HIV-infected~* Androgen deficient, with free testosterone \< 3 pg/mL~* Stable antiretroviral regimen for 3 months prior to study~* Tubal ligation, hysterectomy, or verbalized understanding of appropriate barrier contraception methods. Subjects will be counseled in appropriate barrier contraception methods and the counseling will be documented.~Exclusion Criteria:~* Use of anabolic agent, including testosterone, GH or other preparations within 3 months of the study.~* Use of megestrol acetate within 3 months of the study~* Use of estrogen or any preparation known to affect bone density or bone turnover.This includes oral contraceptives, depo provera or combined progesterone-estrogen injections, and transdermal contraceptive patches.~* Pregnant or breast-feeding~* Hgb \< 9.0 mg/dL~* Current participation in another research study conducted by this investigator or past participation in the DHEA study funded by the same grant as this protocol.~* Creatinine \> 1.5 mg/dL

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 Transdermal Testosterone (Patch) (Type: ACTIVE_COMPARATOR): 300 micrograms applied twice a week
- 2 Placebo Patch (identical in appearance) (Type: PLACEBO_COMPARATOR): placebo patch (0 micrograms of testosterone)applied twice a week

Based on this trial design, predict the completion outcome and termination type (if applicable).